Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): Preliminary results of a preoperative phase exploratory clinical trial

被引：0
|
作者：
Dong, Y. [1 ,2 ]
Luo, J. [3 ]
Liu, S. [4 ]
Lin, Y. [5 ]
Han, H. [5 ]
机构：
[1] Shandong First Med Univ, Shandong Canc Hosp & Inst, Thorac Surg, Jinan, Peoples R China
[2] Shandong Acad Med Sci, Jinan, Peoples R China
[3] Shandong Canc Hosp, Oncol, Jinan, Peoples R China
[4] Shandong Univ, Thorac Surg, Shandong Canc Hosp, Jinan, Peoples R China
[5] Jiangsu Hengrui Pharmaceut Co Ltd, Dept Med, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1225P
引用
收藏
页码：S1109 / S1109
页数：1
相关论文
共 50 条
  • [31] Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study
    Zhang, Yong
    Che, Shaomin
    Chen, Nanzheng
    Li, Xinju
    Fu, Junke
    Yu, Chenao
    Wang, Tianren
    Liang, Runjia
    Xu, Haozhen
    Wu, Qifei
    Jia, Zhuoqi
    Zhu, Cailin
    Gong, Tuotuo
    Li, Haijun
    Zhang, Boxiang
    Hu, Yunyun
    Liu, Yaqi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Neoadjuvant adebrelimab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: A phase 2 trial
    Li, Zhigang
    Yang, Yang
    Liu, Zhichao
    Li, Chunguang
    Su, Yuchen
    Zhang, Hong
    Liu, Jun
    Zhang, Ming
    Dong, Yun
    Han, Yuchen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 443 - 443
  • [33] Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
    Li, Xin
    Xia, Chunqiu
    Liu, Minghui
    Liu, Jinghao
    Dong, Ming
    Zhao, Honglin
    Xu, Song
    Wang, Dan
    Wei, Sen
    Song, Zuoqing
    Chen, Gang
    Liu, Hongyu
    Chen, Jun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study
    Wang, Jianping
    Zhang, Jian
    Gao, Jie
    Zhao, Mengmeng
    Ma, Zhenkai
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (06): : 573 - 581
  • [35] Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.
    Li, Jingpei
    Liu, Jun
    Li, Zhuoyi
    Cui, Fei
    Zeng, Yuan
    Liang, Wenhua
    Liang, Hengrui
    Wang, Wei
    Xu, Ke
    Cai, Weipeng
    Fu, JunHui
    He, Jianxing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] The clinical efficacy of consolidation chemotherapy for resectable esophageal squamous cell cancer after trimodality therapy
    Sun, Yanan
    Cheng, Siguo
    Lu, Yufei
    Zheng, Xiaoli
    Ye, Ke
    Ge, Hong
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 90 - 95
  • [37] Safety And Tolerability Of Neoadjuvant Chemoradiotherapy Combined With Pembrolizumab For Local Advanced, Resectable Esophageal Cancer: Preliminary Results Of A Prospective Phase IB Trial
    Qi, W. X.
    Zhao, S.
    Li, H.
    Chen, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E576 - E577
  • [38] Phase-II study of toripalimab combined with neoadjuvant chemotherapy for the treatment of resectable esophageal squamous cell carcinoma.
    Liu, Delin
    Zhang, Qin
    Zhu, Jinghua
    Qian, Ting
    Yin, Rong
    Fan, Zhaohui
    Jiang, Feng
    Li, Houhuai
    Lu, Jianwei
    Cao, Guochun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.
    Wang, Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Wang, X.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Meng, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
12345